Please assess the completion status of the following clinical trial:

Trial Title: MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Informed Consent Documents signed prior to screening evaluations~* In good physical and mental health~* Pre-menopausal females 21-34 years of age~* Body mass index (BMI)18-25 kg/m2~* Eligible for intracytoplasmic sperm injection (ICSI)~* Unexplained infertility or partner with mild male factor infertility~* Infertility for at least 12 months before randomization~* Regular menstrual cycles of 24-35 days, presumed to be ovulatory~* Hysterosalpingography, hysteroscopy, or transvaginal ultrasound documenting a uterus consistent with expected normal function~* Transvaginal ultrasound documenting expected normal function of the ovaries~* Early follicular phase serum levels of FSH between 1 and 12 IU/L~* Early follicular phase total antral follicle (diameter 2-10 mm) count ≥ 10 for both ovaries combined~* Willing to accept transfer of one blastocyst in the fresh cycle~* Willing to undergo frozen embryo replacement cycles with transfer of one blastocyst per cycle within the first year after randomisation~Exclusion criteria:~* Known polycystic ovarian syndrome or known endometriosis stage I-IV~* Diagnosed as poor responder in a previous controlled ovarian stimulation (COS) cycle~* Severe ovarian hyperstimulation syndrome (OHSS)in a previous COS cycle~* History of recurrent miscarriage~* Current or past (12 months prior to randomization) abuse of alcohol or drugs, and/or current (last month) intake of more than 14 units of alcohol per week~* Current or past smoking habit of more than 10 cigarettes per day~* Hypersensitivity to any active ingredient or excipients in the medicinal products used in the trial~* Hypersensitivity to gonadotrophin-releasing hormone (GnRH) or any other GnRH analogue~* Previous participation in the trial~* Use of any non registered investigational drugs during 3 months before randomization

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 34 Years
- Healthy Volunteers: f

Study Arms:
- Highly Purified Menotrophin (Type: EXPERIMENTAL): None
- Recombinant FSH (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).